GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ALXN1840

Company
Alexion Pharmaceuticals, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT02273596

    Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

    Not yet reported Alexion Pharmaceuticals, Inc. 29 participants Est. completion 2018-11-07 9 sites Stand-alone
    Other conditions: Wilson Disease
    View official trial listing →
  • Terminated NCT NCT03403205

    Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

    Not yet reported Alexion Pharmaceuticals, Inc. 214 participants Est. completion 2023-06-30 56 sites Stand-alone
    Other conditions: Wilson Disease
    View official trial listing →
  • Completed NCT NCT04422431

    Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

    Not yet reported Alexion Pharmaceuticals, Inc. 31 participants Est. completion 2023-05-17 12 sites Stand-alone
    Other conditions: Wilson Disease
    View official trial listing →
  • Completed NCT NCT04526197

    Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

    Not yet reported Alexion Pharmaceuticals, Inc. 36 participants Est. completion 2020-11-03 1 site Stand-alone
    Other conditions: Wilson Disease
    View official trial listing →
  • Completed NCT NCT04526210

    Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

    Not yet reported Alexion Pharmaceuticals, Inc. 54 participants Est. completion 2021-05-28 1 site Stand-alone
    Other conditions: Wilson Disease
    View official trial listing →
  • Completed NCT NCT04560816

    A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

    Not yet reported Alexion Pharmaceuticals, Inc. 57 participants Est. completion 2021-03-24 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04573309

    Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

    Not yet reported Alexion Pharmaceuticals, Inc. 9 participants Est. completion 2022-06-07 3 sites Stand-alone
    Other conditions: Wilson Disease
    View official trial listing →
  • Completed NCT NCT04594252

    Copper Balance in Healthy Participants Administered ALXN1840

    Not yet reported Alexion Pharmaceuticals, Inc. 17 participants Est. completion 2020-11-18 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04610580

    Bioavailability Study of 2 Oral Formulations of ALXN1840

    Not yet reported Alexion Pharmaceuticals, Inc. 48 participants Est. completion 2021-04-26 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT05047523

    Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

    Not yet reported Alexion Pharmaceuticals, Inc. 40 participants Est. completion 2023-06-26 20 sites Stand-alone
    Other conditions: Wilson Disease
    View official trial listing →
  • Completed NCT NCT05303324

    Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults

    Not yet reported Alexion Pharmaceuticals, Inc. 48 participants Est. completion 2019-10-09 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05319899

    A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

    Not yet reported Alexion Pharmaceuticals, Inc. 18 participants Est. completion 2014-03-24 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05319912

    A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

    Not yet reported Alexion Pharmaceuticals, Inc. 18 participants Est. completion 2014-05-29 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05641311

    Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants

    Not yet reported Alexion Pharmaceuticals, Inc. 24 participants Est. completion 2019-05-02 1 site Stand-alone
    Other conditions: Wilson Disease
    View official trial listing →
  • No Longer Available NCT NCT05686564

    Early Access Program for ALXN1840 in Patients With Wilson Disease

    Alexion Pharmaceuticals, Inc.
    Other conditions: Wilson Disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.